Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren's syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren's Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology. Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.

"This book is a comprehensive and up-to-date review of Lupus Erythematosus and related syndromes written by over 100 experts in the field. The previous edition was published in 2018." -©Doody’s Review Service, 2024, Massoud Mahmoudi, DO, PhD (University of California San Francisco)

• SECTION 1 What Is Lupus?1. History of Lupus2. Definition and Classification of Lupus and Lupus-Related Disorders3. The Epidemiology of LupusSECTION 2 Pathogenesis4. Overview of Lupus Pathogenesis5. Genetics of SLE6. Single Gene Defects and Autoinflammation: Relation to Lupus7. Epigenetics of Lupus8. The Role of the Environment and Microbiome in Lupus9. The Innate Immune System in SLE10. B Cells and Generation of Antibodies11. T cells12. Immunoregulatory Cells and Networks in Lupus13. Cytokines in Lupus14. Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus15. Animal Models of Systemic Lupus Erythematosus (SLE)SECTION 3 Mechanisms of Tissue Injury16. Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus17. Complement and Systemic Lupus Erythematosus18. Apoptosis and Inflammatory Forms of Cell Death19. Tissue Damage in Lupus: Free Radicals and Fibrosis20. Lupus Nephritis21. Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus22. Pathogenesis of Cutaneous Lupus23. Pathogenesis of Neuropsychiatric Lupus24. Pathogenesis of Sjögren SyndromeSECTION 4 Autoantibodies25. Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes26. Antibodies Against Extractable Nuclear Antigens (RNP, Sm, SS-A/Ro, and SS-B/La)27. Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells28. Pathogenesis of Antiphospholipid Antibody Syndrome29. Drug-Induced LupusSECTION 5 Clinical Aspects of Lupus Erythematosus30. Overview and Clinical Presentation31. Skin Disease in Cutaneous Lupus Erythematosus32. The Musculoskeletal System and Bone Metabolism33. Lupus and the Cardiovascular System34. Pulmonary Manifestations of Systemic Lupus Erythematosus35. Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment36. Gastrointestinal and Hepatic Manifestations37. The Gut Microbiome and Lupus Pathogenesis38. Hematologic and Lymphoid Abnormalities in SLE39. Neonatal Lupus: Pathogenesis and Clinical Approaches40. Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus41. Systemic Lupus Erythematosus in Childhood and Adolescence42. Clinical Aspects of Antiphospholipid Syndrome43. Lupus and Infections44. Ocular, Aural, and Oral Manifestations of Lupus45. Clinical Aspects of Sjögren’s Disease46. Clinical Presentations of Lupus in the Kidney and Urogenital System47. The Endocrine System and Hormones in LupusSECTION 6 Assessment of Lupus48. Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus49. Differential Diagnosis and Disease Associations50. Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease51. Clinical Markers, Metrics, Indices, and Clinical TrialsSECTION 7 Management of Lupus52. Principles of Therapy, Local Measures, and NSAIDs53. Antimalarial Medications54. Systemic Glucocorticoid Therapy for SLE55. Immunosuppressive Drug Therapy56. Complementary and Integrative Health Approaches57. Specialized and Niche Therapies58. Adjunctive and Preventive Measures59. Management of Cutaneous Lupus Erythematosus60. Targeted Therapies in SLE61. Management of Lupus Nephritis62. Management of Sjögren Disease SyndromeSECTION 8 Outcomes63. Socioeconomics, Disparities, and Disability64. Prognosis and Mortality of Systemic Lupus Erythematosus65. Future Directions: Therapeutics66. Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations

Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren's syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren's Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology. Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.

"This book is a comprehensive and up-to-date review of Lupus Erythematosus and related syndromes written by over 100 experts in the field. The previous edition was published in 2018." -©Doody’s Review Service, 2024, Massoud Mahmoudi, DO, PhD (University of California San Francisco)

• SECTION 1 What Is Lupus?1. History of Lupus2. Definition and Classification of Lupus and Lupus-Related Disorders3. The Epidemiology of LupusSECTION 2 Pathogenesis4. Overview of Lupus Pathogenesis5. Genetics of SLE6. Single Gene Defects and Autoinflammation: Relation to Lupus7. Epigenetics of Lupus8. The Role of the Environment and Microbiome in Lupus9. The Innate Immune System in SLE10. B Cells and Generation of Antibodies11. T cells12. Immunoregulatory Cells and Networks in Lupus13. Cytokines in Lupus14. Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus15. Animal Models of Systemic Lupus Erythematosus (SLE)SECTION 3 Mechanisms of Tissue Injury16. Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus17. Complement and Systemic Lupus Erythematosus18. Apoptosis and Inflammatory Forms of Cell Death19. Tissue Damage in Lupus: Free Radicals and Fibrosis20. Lupus Nephritis21. Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus22. Pathogenesis of Cutaneous Lupus23. Pathogenesis of Neuropsychiatric Lupus24. Pathogenesis of Sjögren SyndromeSECTION 4 Autoantibodies25. Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes26. Antibodies Against Extractable Nuclear Antigens (RNP, Sm, SS-A/Ro, and SS-B/La)27. Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells28. Pathogenesis of Antiphospholipid Antibody Syndrome29. Drug-Induced LupusSECTION 5 Clinical Aspects of Lupus Erythematosus30. Overview and Clinical Presentation31. Skin Disease in Cutaneous Lupus Erythematosus32. The Musculoskeletal System and Bone Metabolism33. Lupus and the Cardiovascular System34. Pulmonary Manifestations of Systemic Lupus Erythematosus35. Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment36. Gastrointestinal and Hepatic Manifestations37. The Gut Microbiome and Lupus Pathogenesis38. Hematologic and Lymphoid Abnormalities in SLE39. Neonatal Lupus: Pathogenesis and Clinical Approaches40. Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus41. Systemic Lupus Erythematosus in Childhood and Adolescence42. Clinical Aspects of Antiphospholipid Syndrome43. Lupus and Infections44. Ocular, Aural, and Oral Manifestations of Lupus45. Clinical Aspects of Sjögren’s Disease46. Clinical Presentations of Lupus in the Kidney and Urogenital System47. The Endocrine System and Hormones in LupusSECTION 6 Assessment of Lupus48. Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus49. Differential Diagnosis and Disease Associations50. Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease51. Clinical Markers, Metrics, Indices, and Clinical TrialsSECTION 7 Management of Lupus52. Principles of Therapy, Local Measures, and NSAIDs53. Antimalarial Medications54. Systemic Glucocorticoid Therapy for SLE55. Immunosuppressive Drug Therapy56. Complementary and Integrative Health Approaches57. Specialized and Niche Therapies58. Adjunctive and Preventive Measures59. Management of Cutaneous Lupus Erythematosus60. Targeted Therapies in SLE61. Management of Lupus Nephritis62. Management of Sjögren Disease SyndromeSECTION 8 Outcomes63. Socioeconomics, Disparities, and Disability64. Prognosis and Mortality of Systemic Lupus Erythematosus65. Future Directions: Therapeutics66. Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations

Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren's syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren's Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology. Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.

"This book is a comprehensive and up-to-date review of Lupus Erythematosus and related syndromes written by over 100 experts in the field. The previous edition was published in 2018." -©Doody’s Review Service, 2024, Massoud Mahmoudi, DO, PhD (University of California San Francisco)

• SECTION 1 What Is Lupus?1. History of Lupus2. Definition and Classification of Lupus and Lupus-Related Disorders3. The Epidemiology of LupusSECTION 2 Pathogenesis4. Overview of Lupus Pathogenesis5. Genetics of SLE6. Single Gene Defects and Autoinflammation: Relation to Lupus7. Epigenetics of Lupus8. The Role of the Environment and Microbiome in Lupus9. The Innate Immune System in SLE10. B Cells and Generation of Antibodies11. T cells12. Immunoregulatory Cells and Networks in Lupus13. Cytokines in Lupus14. Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus15. Animal Models of Systemic Lupus Erythematosus (SLE)SECTION 3 Mechanisms of Tissue Injury16. Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus17. Complement and Systemic Lupus Erythematosus18. Apoptosis and Inflammatory Forms of Cell Death19. Tissue Damage in Lupus: Free Radicals and Fibrosis20. Lupus Nephritis21. Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus22. Pathogenesis of Cutaneous Lupus23. Pathogenesis of Neuropsychiatric Lupus24. Pathogenesis of Sjögren SyndromeSECTION 4 Autoantibodies25. Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes26. Antibodies Against Extractable Nuclear Antigens (RNP, Sm, SS-A/Ro, and SS-B/La)27. Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells28. Pathogenesis of Antiphospholipid Antibody Syndrome29. Drug-Induced LupusSECTION 5 Clinical Aspects of Lupus Erythematosus30. Overview and Clinical Presentation31. Skin Disease in Cutaneous Lupus Erythematosus32. The Musculoskeletal System and Bone Metabolism33. Lupus and the Cardiovascular System34. Pulmonary Manifestations of Systemic Lupus Erythematosus35. Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment36. Gastrointestinal and Hepatic Manifestations37. The Gut Microbiome and Lupus Pathogenesis38. Hematologic and Lymphoid Abnormalities in SLE39. Neonatal Lupus: Pathogenesis and Clinical Approaches40. Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus41. Systemic Lupus Erythematosus in Childhood and Adolescence42. Clinical Aspects of Antiphospholipid Syndrome43. Lupus and Infections44. Ocular, Aural, and Oral Manifestations of Lupus45. Clinical Aspects of Sjögren’s Disease46. Clinical Presentations of Lupus in the Kidney and Urogenital System47. The Endocrine System and Hormones in LupusSECTION 6 Assessment of Lupus48. Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus49. Differential Diagnosis and Disease Associations50. Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease51. Clinical Markers, Metrics, Indices, and Clinical TrialsSECTION 7 Management of Lupus52. Principles of Therapy, Local Measures, and NSAIDs53. Antimalarial Medications54. Systemic Glucocorticoid Therapy for SLE55. Immunosuppressive Drug Therapy56. Complementary and Integrative Health Approaches57. Specialized and Niche Therapies58. Adjunctive and Preventive Measures59. Management of Cutaneous Lupus Erythematosus60. Targeted Therapies in SLE61. Management of Lupus Nephritis62. Management of Sjögren Disease SyndromeSECTION 8 Outcomes63. Socioeconomics, Disparities, and Disability64. Prognosis and Mortality of Systemic Lupus Erythematosus65. Future Directions: Therapeutics66. Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations